Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells  by Toledo, Chad M. et al.
ArticleGenome-wide CRISPR-Cas9 Screens Reveal Loss of
Redundancy between PKMYT1 and WEE1 in
Glioblastoma Stem-like CellsGraphical AbstractHighlightsd CRISPR-Cas9 lethality screens performed in patient brain-
tumor stem-like cells
d PKMYT1 is identified in GSCs, but not NSCs, as essential for
facilitating mitosis
d PKMYT1 and WEE1 act redundantly in NSCs, where their
inhibition is synthetic lethal
d PKMYT1 and WEE1 redundancy can be broken by over-
activation of EGFR and AKTToledo et al., 2015, Cell Reports 13, 2425–2439
December 22, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.celrep.2015.11.021Authors
Chad M. Toledo, Yu Ding,
Pia Hoellerbauer, ..., Bruce E. Clurman,
James M. Olson, Patrick J. Paddison
Correspondence
jolson@fredhutch.org (J.M.O.),
paddison@fredhutch.org (P.J.P.)
In Brief
Patient-derived glioblastoma stem-like
cells (GSCs) can be grown in conditions
that preserve patient tumor signatures
and their tumor initiating capacity. Toledo
et al. use these conditions to perform
genome-wide CRISPR-Cas9 lethality
screens in both GSCs and non-
transformed NSCs, revealing PKMYT1 as
a candidate GSC-lethal gene.
Cell Reports
ArticleGenome-wide CRISPR-Cas9 Screens Reveal Loss
of Redundancy between PKMYT1 andWEE1
in Glioblastoma Stem-like Cells
Chad M. Toledo,1,2,14 Yu Ding,1,14 Pia Hoellerbauer,1,2 Ryan J. Davis,1,2,3 Ryan Basom,4 Emily J. Girard,3 Eunjee Lee,5
Philip Corrin,1 Traver Hart,6,7 Hamid Bolouri,1 Jerry Davison,4 Qing Zhang,4 Justin Hardcastle,1 Bruce J. Aronow,8
Christopher L. Plaisier,9 Nitin S. Baliga,9 Jason Moffat,6,7 Qi Lin,10 Xiao-Nan Li,10 Do-Hyun Nam,11 Jeongwu Lee,12
Steven M. Pollard,13 Jun Zhu,5 Jeffery J. Delrow,4 Bruce E. Clurman,1,3 James M. Olson,3,* and Patrick J. Paddison1,2,*
1Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
2Molecular and Cellular Biology Program, University of Washington, Seattle, WA 98195, USA
3Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
4Genomics and Bioinformatics Shared Resources, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
5Department of Genetics and Genomic Sciences, Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount
Sinai, New York, NY 10029, USA
6Department of Molecular Genetics, University of Toronto and Donnelly Centre, Toronto, ON M5S3E1, Canada
7Canadian Institute for Advanced Research, Toronto, ON M5G1Z8, Canada
8Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
9Institute for Systems Biology, Seattle, WA 98109, USA
10Brain Tumor Program, Texas Children’s Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
11Institute for Refractory Cancer Research, Samsung Medical Center, Seoul 135-710, Korea
12Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44192, USA
13Edinburgh CRUK Cancer Research Centre and MRC Centre for Regenerative Medicine, The University of Edinburgh, Edinburgh
EH16 4UU, UK
14Co-first author
*Correspondence: jolson@fredhutch.org (J.M.O.), paddison@fredhutch.org (P.J.P.)
http://dx.doi.org/10.1016/j.celrep.2015.11.021
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARY
To identify therapeutic targets for glioblastoma
(GBM), we performed genome-wide CRISPR-Cas9
knockout (KO) screens in patient-derived GBM
stem-like cells (GSCs) and human neural stem/pro-
genitors (NSCs), non-neoplastic stem cell controls,
for genes required for their in vitro growth. Surpris-
ingly, the vast majority GSC-lethal hits were found
outside of molecular networks commonly altered in
GBM and GSCs (e.g., oncogenic drivers). In vitro
and in vivo validation of GSC-specific targets re-
vealed several strong hits, including the wee1-like
kinase, PKMYT1/Myt1. Mechanistic studies demon-
strated that PKMYT1 acts redundantly with WEE1
to inhibit cyclin B-CDK1 activity via CDK1-Y15 phos-
phorylation and to promote timely completion of
mitosis in NSCs. However, in GSCs, this redundancy
is lost, most likely as a result of oncogenic signaling,
causing GBM-specific lethality.INTRODUCTION
One popular concept in cancer research is the notion that
genomic and molecular profiling of patient samples will enableCell Repthe discovery of patient-tailored therapeutic strategies. How-
ever, it remains unclear whether analytic or computational ap-
proaches based solely on descriptive datasets are powerful
enough to predict successful therapies. An alternative
approach is to directly identify molecular vulnerabilities in pa-
tient samples using functional genetic experimentation. This
has recently been achieved for glioblastoma (GBM) (Chudnov-
sky et al., 2014; Ding et al., 2013; Gargiulo et al., 2013; Goidts
et al., 2012; Hubert et al., 2013; Kitambi et al., 2014; Toledo
et al., 2014; Wurdak et al., 2010), the most aggressive and
common form of brain cancer in adults (American Cancer Soci-
ety, 2010; Stupp et al., 2005).
Loss of gene function RNAi screens have been performed
directly in patient-derived GBM stem-like cells (GSCs) for candi-
date therapeutic targets and GBM regulatory networks (Chud-
novsky et al., 2014; Ding et al., 2013; Gargiulo et al., 2013; Goidts
et al., 2012; Hubert et al., 2013; Toledo et al., 2014;Wurdak et al.,
2010). GSCs retain tumor-initiating potential and tumor-specific
genetic and epigenetic signatures in vitro (Lee et al., 2006;
Pollard et al., 2009), under culture conditions that mimic the neu-
ral progenitor perivascular niche (Kazanis et al., 2010; Lathia
et al., 2012). By performing control screens in fetal neural stem
cells (NSCs), which have similar expression profiles and devel-
opmental potential but are not transformed (Lee et al., 2006;
Pollard et al., 2009), candidate GSC-specific therapeutic targets
can be identified (Ding et al., 2013; Hubert et al., 2013; Toledo
et al., 2014).orts 13, 2425–2439, December 22, 2015 ª2015 The Authors 2425
With the emergence of CRISPR-Cas9 gene editing technol-
ogy, functional genetic single-guide RNA (sgRNA) libraries now
exist that are in theory capable of triggering biallelic insertion-
deletion (indel) mutations in most genes in the human genome
(Shalem et al., 2014; Wang et al., 2014). In contrast to gene
knockdown, these indels can cause knockout (KO)-like mu-
tations that result in frameshifts in target genes leading to pre-
mature stop codons, non-sense mediated mRNA decay, and
complete loss of protein function (Mali et al., 2013; Wiedenheft
et al., 2012). However, this technology may present unique chal-
lenges for studying essential genes in mammals. For example, if
Cas9 cuts are repaired by the non-homologous end-joining
pathway in a non-biased manner, one-third of the time a small
in-frame indel would be generated that might have little effect
on protein activity.
Here, we applied a genome-wide CRISPR-Cas9 library to
GSCs and NSCs in an attempt to further identify GBM candi-
date therapeutic targets, which when KO’d are essential to
GSCs but non-essential in NSCs, suggestive of a large thera-
peutic window. The results from these screens provide evi-
dence for both ‘‘individual’’ GSC-specific KO hits, which are
found only in individual patient samples, and ‘‘convergent’’
KO hits, which are shared hits between GBM-isolates of
different developmental subtypes and genetic alterations.
Follow-up studies were focused on a strongly scoring ‘‘conver-
gent’’ screen hit, PKMYT1/Myt1 (Booher et al., 1997; Liu et al.,
1997). We find that PKMYT1 and WEE1 are redundant and
synthetic lethal in NSCs, where they redundantly phos-
phorylate CDK1-Y15 and block premature entry into mitosis.
However, this redundancy is broken in GSCs or NSCs overex-
pressing activated alleles of EGFR and AKT1, which results in
the essential requirement for PKMYT1 and timely completion
of mitosis. Further, we also demonstrate that repair of
CRISPR-Cas9-triggered indels exhibit frameshift bias, causing
more out-of-frame indels than expected by chance, which
explains the effectiveness of this technology. Our results sug-
gest that PKMYT1 is a candidate therapeutic target for GBM.
More generally, our results illustrate the utility of performing
CRISPR-Cas9 screens for essential genes in patient tumor
samples.
RESULTS
Genome-wide CRISPR-Cas9 Screens in Human GSCs
and NSCs
We first examined the efficacy of delivering a CRISPR-Cas9 tar-
geting system by lentiviral (LV) transduction in human GSC and
NSC isolates. Consistent with previous reports, an all-in-one
LV-sgRNA:Cas9 platform system was highly effective at target-
ing reporter and endogenous genes in both GSCs and NSCs
(Figures 1A–1D), including randomly integrated copies of EGFP
(>85%), a non-essential endogenous gene, TP53, assayed by
western blot, and an essential gene, MCM2 (O’Donnell et al.,
2013), assayed by viability of in vitro expanded cells. In each
case, we were able to observe profound reduction in target
gene activity in GSCs and NSCs. Importantly, peak suppression
occurred 10–14 days post-selection and non-targeting sgRNA
controls had no effect on cell viability (Figure 1).2426 Cell Reports 13, 2425–2439, December 22, 2015 ª2015 The AuWe next performed genome-wide screens using two adult
GSC isolates, 0131 and 0827 (Son et al., 2009), and two control
NSC lines, CB660 and U5 (Figure 2A). These GSC isolates best
resemble mesenchymal and proneural GBM subtypes, respec-
tively (Figure S2), two subtypes accounting for over half of adult
GBM cases (Verhaak et al., 2010). These isolates harbor charac-
teristic gene and pathway alterations commonly observed in
GBM tumors (Brennan et al., 2013), including alterations in
EGFR, NF1, MDM2/4, PI3KCA, PTEN, RB1, TERT, and/or
TP53 (Figures 2A and S1A–S1D; Table S1). Importantly, we did
not find growth defects in NSCs or GSCs when Cas9 was stably
expressed for over 3 weeks (Figure S1E).
The screens were performed using a ‘‘shot gun’’ approach
where GSCs and NSCs were transduced with a LV pool con-
taining a human CRISPR-Cas9 library composed of 64,751
unique sgRNAs targeting 18,080 genes (Shalem et al., 2014)
and outgrown in self-renewal conditions for 3 weeks (day
21 for NSC-U5 or day 23 for all others) (Supplemental Exper-
imental Procedures) using two biological replicates per
isolate. For the primary screen readout, we deep sequenced
library sgRNAs from transduced cell populations before and
after outgrowth. Based on normalized read counts, we identi-
fied 99.8% of all sgRNAs in the library pool. Each screen
replicate tightly clustered at day 0 but displayed cell-type-
specific differences after expansion (Figure 2B). Importantly,
sgRNA sequence reads were well correlated between bio-
logical replicates with Pearson’s r values of 0.98 for all day
0 replicates and R0.79 for 3-week-outgrown replicates
(Figure S2A).
To assess changes in individual sgRNA representation, edgeR
(empirical analysis of digital gene expression in R) was used
(Robinson et al., 2010) (Supplemental Experimental Procedures).
While edgeR has been mainly used for examining changes in
steady-state mRNA levels from SAGE and RNA sequencing
(RNA-seq) data, by design, edgeR was intended for use with
any type of count based sequence tag data in complex libraries,
including nucleic acid bar codes (Dai et al., 2014). To do so,
edgeR models the count variance across replicates as a
nonlinear function of the mean counts using a negative binomial
distribution while accounting for over all data dispersion. The
output of edgeR provides fold changes for each individual
sgRNA’s sequenced reads, in our case, between day 21 or 23
and day 0 and also provides a statistical test similar to a Fisher’s
exact test to determine significance. This approach revealed
thousands of significantly scoring sgRNAs for each screen at
day 21 or 23, representing both candidate essential and growth
limiting genes (Figure 2C; Table S2).
To assess screen and edgeR performance, we employed a
Bayesian classifier that uses predetermined essential and non-
essential gene training sets to help determine functional genetic
screen quality (Hart et al., 2014) (Figures S2B–S2D; Table S3).
This analysis allowed independent scoring of essential genes
in each isolate, supporting observations reported below for
edgeR analysis (Figure S2E).
Further, given that CRISPR-Cas9 technology relies on
nuclease cleavage of target sites, there is the possibility that
copy-number variation (CNV) in target sites could affect screen
outcome. Using hypergeometric testing, we did not observethors
AB
C
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Figure 1. Validation of CRISPR-Cas9-Based Gene Targeting in Human GSCs and NSCs
(A) Cartoon of lentiviral construct used for sgRNA:Cas9 expression.
(B) sgEGFP:Cas9 was used to target stably expressed H2B-EGFP in GSCs and NSCs. Cells were first infected with LV-EGFP-H2B at MOI >2 and passaged for
1 week and then infected with sgControl or sgEGFP at MOI <1, selected, outgrown for 14 days, and flow analyzed. Similar results were obtained for each NSC-
CB660s and GSC-0131s (data not shown). At day 5 post-selection, for EGFP+sgEGFP NSC-CB660s, we noted 19.5% of cells still positive for GFP, while by D12,
this number was reduced to <1%, suggesting that peak suppression probably occurs around D10 for a single, mono-allelic genomic target. However, a small
percentage of wild-type (non-edited) cells remained at D12 post-selection after targeting the endogenous gene CREBBP (Figure 7), and, thus, the peak sup-
pression occurs between D10 and D14 depending on the target.
(C) Western blot confirmation of TP53 protein expression after targeting TP53 gene with sgRNA:Cas9 in NSC-U5s. Cells were outgrown for >21 days following
selection. Doxorubicin treatment (0.75 mg/ml for 6 hr) was used to stabilize TP53 in response to DNA damage.
(D) CRISPR-Cas9-based targeting of an essential gene, MCM2. Cells were infected with sgRNAs and seeded 3 days post-selection for a 10-day culture in
triplicate. Cell viability was then measured using alamarBlue reagent. *p < 0.01, Student’s t test (unpaired, unequal variance).enrichment of GSC screen hits at specific genome addresses,
nor did we observe enrichment for genes contained within sites
of GSC-specific CNV among screen hits (data not shown). This
suggests that CNV differences in GSCs were not a major factor
affecting screen outcomes.
Gene set enrichment analysis (GSEA) for each screen identi-
fied core cellular processes, including translation, RNA splicing,
and DNA replication, among others (Figures 2D and S3A–S3C;
Table S4). This indicated that the screens were effective at
revealing essential gene targets, which is consistent with previ-
ous use of this library (Shalem et al., 2014). Interestingly, how-
ever, each screen was enriched for genes involved in cerebrum
and CNS development, suggesting that each of the isolates re-
tains the function of brain-specific gene networks (Figure 2E).
Closer examination of these hits revealed genes with critical
roles in regulating asymmetric and symmetric divisions of neural
progenitors during cortical development (Figure 2F)(Sun and
Hevner, 2014), consistent with GSCs and NSCs sharing underly-
ing neuroprogenitor biology.
Interestingly, among hits specifically enriched in NSCs
screens, but not GSCs, were sgRNAs belonging to the Fanconi
anemia pathway gene network (Figures 2F and S3D), which isCell Reprequired to suppress apoptosis in mouse neural progenitors
(Sun and Hevner, 2014), and also a network of citric acid cycle
and respiratory electron transport genes (Figure S3D). The latter
is consistent with the notion that GBM cells experience the
Warburg effect where metabolism shifts from oxidative phos-
phorylation to lactate production (Wu et al., 2014).
GSC-Specific CRISPR-Cas9 Screen Hits Fall Outside of
Core Genes and Pathways Altered in GBM
We next wondered whether our screen hits would be biased to-
ward inclusion of gene hits found in networks and pathways
commonly found altered in GBM and in our patient isolates.
For example, the concept of ‘‘oncogene addiction’’ predicts
that cancer cells should differentially require oncogene activities
to which they are ‘‘addicted’’ (Weinstein and Joe, 2008). To this
end, patient-specific GBM networks were created by mapping
the results from genomic data from GSC-0131 and GSC-0827
(i.e., RNA-seq, CNV, and exome-seq) onto genes and pathways
commonly altered in GBM from TCGA data (e.g., p53, PI3K,
Rb-Axis, etc.) (Figure S4). We then incorporated GSC specific le-
thal screens hits, which also did not score in NSCs (to model
therapeutic window).orts 13, 2425–2439, December 22, 2015 ª2015 The Authors 2427
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Figure 2. Genome-wide CRISPR-Cas9 KO Screens in GSCs and NSCs
(A) Overview of GSC and NSC isolates used and screen procedure.
(B) Principal component analysis of sgRNA-sequencing results of biological screen replicates.
(C) Scatterplots showing log2 normalized library sgRNA read counts comparing day 21 or 23 to day 0 . Each dot represents a specific sgRNAs. Red dots indicate
significantly overrepresented sgRNAs (LogFC >1, false discover rate [FDR] <0.05), while green dots indicate significantly underrepresented sgRNAs (LogFC <1,
FDR <0.05) after outgrowth. HEATR1 and MCM2 were top scoring essential gene hits, while TP53 showed strong enrichment in NSC screens.
(D) GSEA for gene ontology biological processes terms was conducted on all sgRNAs from screen results. Top 5 depleted gene sets in NSC-CB660 (FDR-
corrected q < 0.0001) and GSC-0827 (FDR-corrected q < 0.011, 0.010, 0.012, 0.057, and 0.070 respectively) are displayed. Green line represents the point where
the ratios (end point of screen/day 0) change from positive (left) to negative (right). Red line represents the point where the running sum statistic has its maximum
deviation from 0 (enrichment score).
(E) Overlapping human phenotype ontology gene sets enriched among candidate sensitive hits (logFC < 1.0, FDR < 0.05). Each set shown was among top ten
gene sets enriched.
(F) Significant screen hits (logFC <1, FDR <0.05) were overlapped with genes involved in cortical neural progenitor (NP) organization or orientation and the
Fanconi anemia pathway. A gene was scored if one or more sgRNA(s) per gene met the criterion.Surprisingly, only 10 GSC-specific hits out of 946 total (Fig-
ure 2A) overlapped core pathways altered in GBM (Figure S4A).
For GSC-0131s, only four genes were in the network: CCNE1,
MLST8, SREBF2, and TP53. None of these genes are altered2428 Cell Reports 13, 2425–2439, December 22, 2015 ª2015 The Auin the descriptive genomics data from these patient samples,
except for TP53. GSC-0131s have a homozygous TP53V147D
mutation (Table S1), which alters the requirement for MDM2
and MDM4 (as judged by loss of sgMDM2/4 in TP53wt isolates,thors
but not GSC-0131s) and how sgRNAs targeting TP53 score
(GSC-0131s possibly have a reliance on mutant TP53)
(Figure S1F).
For GSC-0827s, seven screen hits were in its network (i.e.,
AKT1,ERBB3,GAB1,MLST8,NFKB1,PRKCA, andPRKCI) (Fig-
ure S4B). Of these, four have missense mutations of unknown
function and two are overexpressed (relative to NSCs). However,
because this isolate is a mutator (Figure S1D), many genes in the
network are altered. GSC-0827s have an activating mutation in
PI3KCA and also an EGFR amplification andmutation. However,
these were not among the screen hits. Thus, counter to the
notion of ‘‘oncogene addiction,’’ this analysis suggested that
core pathways altered in GBM are not good predictors of
CRISPR-Cas9-based lethality, as the majority of GBM lethal
hits (>95%) occur outside of core GBM altered pathways. One
caveat though is that we do not know whether each library
sgRNA is effective at targeting each gene in the GBM network;
another is that these screens are not perfect with respect to pre-
cision and recall (Figure S2C) or retest rate (see below).
Validation of Essential and GSC-Sensitive Genes In Vitro
and In Vivo
To initially validate lethal screen hits, we created a retest pool
consisting of 7 essential genes and 51 GSC-sensitive genes
picked with bias toward genes coding for proteins with enzy-
matic function (e.g., PKMYT1 kinase), or part of complexes
with enzymatic activity (e.g., FBXO42 E3 ubiquitin ligase com-
plex) or transcriptional activity (e.g., transcription factor AP-2
gamma, TFAP2C) from edgeR analysis (three to four sgRNAs
per gene) comparing GSCs to NSCs sgRNAs with logFC < 1
(Figure 3A). We first examined performance of individual sgRNAs
from the pool in in vitro growth assays in NSC-CB660s, GSC-
0131s, and GSC-0827s, testing 47 individual sgRNAs (approxi-
mately two sgRNAs per gene) (Figures 3B and S5A; Table S6).
Of 47 sgRNAs tested, 27 (57%) scored in a manner consistent
with the initial screen, which included PKMYT1, candidate
GSC-sensitive gene, andHEATR1, candidate top scoring essen-
tial gene that is involved in rDNA transcription (Prieto and
McStay, 2007) (Figures 3B and S5A).
Next, we performed parallel screens with the full retest pool
both in vitro in GSCs and NSCs and in vivo in tumors derived
fromGSC cells. For the in vitro retest screens, two biological rep-
licates of NSC-CB660, GSC-0131, and GSC-0827 cell pools
were outgrown for 21 days similar to the primary screen. For
the in vivo tumor formation, five independently derived tumors
were analyzed from GSC-0131s and GSC-0827s infected with
the retest pools (Supplemental Experimental Procedures). Like
the main screen, the results were assayed by the changes in
sgRNA representation either at day 21 for in vitro studies or after
tumor formation for in vivo studies compared to day 0. Heatmaps
representing the change in representation for all sgRNAs in the
pool are shown in Figure 3C for in vitro and in vivo results, with
callouts for genes that scored prominently as cancer-sensitive
or essential. Analysis of in vitro versus in vivo results for this anal-
ysis suggested good concordance of changes in replication
(R2 = 0.59 for GSC-0131s; R2 = 0.83 for GSC-0827s) (Figures
S5B and S5C). GSC-0131s had 22 screen hits displaying signif-
icant loss of representation relative to control and EGFP sgRNAsCell Rep(R2 sgRNAs with –logFC, p < 0.05), while GSC-0827s had 17
screens hits meeting the same criteria (Figures S5B and S5C).
Comparing in vitro GSC and NSC data revealed 18 hits with
two or more sgRNAs at logFC% 1.0 for GSC-0131 and seven
hits meeting the same criteria for GSC-0827 (Figures S5D and
S5E). Both in vitro and in vivo retests yielded PKMYT1 as the
top ‘‘convergent’’ GSC-lethal gene. Other hits consistent with
original screen results included: FBXO42 (0827 specific),
HDAC2 (0827 specific), and TFAP2C (0131 specific), among
others (Figure 3C).
Comparisons with Short Hairpin RNA Screens
Performed in GSCs and NSCs
Since the CRISPR-Cas9 screens produced results consistent
with identification of GSC-lethal genes, we also compared the
results to previously performed genome-wide short hairpin
RNA (shRNA) screens conducted in NSC-CB660, GSC-0131,
and GSC-0827 cells in identical outgrowth conditions, which
also producedGSC-specific hits (Hubert et al., 2013). Consistent
with CRISPR-Cas9 screens preferentially identifying essential
genes, there was greater number of total ‘‘essential hits’’ in
sgRNA screens predicted to be lethal to all isolates (769 versus
95) (Figure S6). There was an agreement between GSC-sensitive
hits from both screens for several networks and pathways,
including pre-mRNA splicing, which includes genes previously
reported as GSC-sensitive involved in 30 splice-site recognition
(Hubert et al., 2013); control of the G2/M transition, including
two key negative regulators of cyclin B/CDK1 activity, PKMYT1
and WEE1; DNA damage checkpoint, including ATRIP, MDC1,
and CLSPN; members of COP9 signalosome complex (Lee
et al., 2011), among others. Importantly, several nodes among
these complexes, includingPKMYT1 andCAB39, were validated
in the course of our sgRNA retests (Figure 3C). The results sug-
gest that these pathways and complexes cross-validate be-
tween the two technology platforms as GBM-sensitive.
PKMYT1 KO Causes Lethality in Multiple GSC Isolates
To further evaluate retesting sgRNA screen hits, we next exam-
ined targeting of PKMYT1, FBXO42, HDAC2, TFAP2C, and
HEATR1 in ten different GSC isolates along with NSCs using
in vitroviability assaysand twocontrol sgRNAs (Figure3E). The re-
sults revealed that PKMYT1 was required for viability in eight of
these isolates, while HDAC2 and TFAP2C requirement appeared
more specific to GSC-0827s andGSC-0131s, respectively. How-
ever, targeting of FBXO42, which can promote ubiquitination and
degradation of p53 (Sun et al., 2009), showed profound sensitivity
in both the GSC-0827 and GSC-G166 isolates (Figure 3E). This
likely indicates that patient-specific genetic or epigenetic alter-
ations drive differential requirement for these genes. In contrast,
HEATR1 sgRNAs were lethal to all isolates examined (Figure 3E),
demonstrating that the differences in GSC-specific requirement
for the other genes are not technical artifacts.
Molecular and Phenotypic Analysis of PKMYT1
Depletion
Since PKMYT1 emerged as a robust GSC-sensitive hit both
in vivo and in vitro among our retests, we wished to further vali-
date it as a candidate therapeutic target for GBM. PKMYT1 (akaorts 13, 2425–2439, December 22, 2015 ª2015 The Authors 2429
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Figure 3. Validation of CRISPR-Cas9 Screen Hits Required for GSC Expansion In Vitro and In Vivo
(A) Venn diagram showing overlap among candidate genes. sgRNAs with logFC <1.0 (FDR <0.05) were considered candidate sensitive genes. For simplicity,
NSC-U5 and NSC-CB660 were combined.
(B) Heatmap of retested candidate sensitive individual sgRNAs (two sgRNAs/gene; 23 genes). Cells were infected with lentivirus containing individual sgRNAs,
and cultured (15–22 days) in triplicate. Overall, growth of each sgRNA was calculated and normalized to sgControl. Each sgRNA was categorized as essential,
GBM sensitive, or patient-specific according to screen results and then compared. Figure S5 contains sgRNAs scores, Table S5 contains individual sgRNA
sequences used in retest, and Table S6 contains source data.
(C) Heatmap of retested in vivo and in vitro pools (58 genes; three to four sgRNAs/gene). For in vivo studies, GSCs were injected into mice (n = 5) following
selection (see Supplemental Experimental Procedures). Tumorswere cut into two, sequenced, and scored using limma. -T, tumor. Table S6 contains source data.
(D) STRING network (Szklarczyk et al., 2015) representations of GSC-specific hits scoring in pooled retest assays, along with other GSC-specific hits either
scoring in CRISPR-Cas9 or shRNA genome-wide screens (see text and also Figure S5 for details of sgRNA and shRNA screen comparisons).
(legend continued on next page)
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Myt1) encodes a dual specificity protein kinase homologous to
WEE1 that localizes to the ER-Golgi complex and, at least
in vitro, can inhibit cyclin B-CDK1 activity, by phosphorylating
CDK1’s ATP binding domain at T14 and to a lesser extent Y15
(Booher et al., 1997; Liu et al., 1997). WEE1, by contrast, has
been shown to phosphorylate Y15 of both CDK1/2 but is inca-
pable of phosphorylating T14 (Watanabe et al., 1995). Genetic
experiments in Drosophila suggest that PKMYT1 andWEE1 ho-
mologs act redundantly during fly development (Jin et al., 2008).
However, loss-of-function experiments in mammals, which have
been performed mainly in HeLa cells, suggest that human
PKMYT1 andWEE1 are not functionally equivalent. For example,
knockdown of WEE1 in HeLa cells induces loss of Y15 phos-
phorylation, premature entry into mitosis before completion of
DNA replication (i.e., mitotic catastrophe), and apoptosis (Naka-
jima et al., 2008),(Coulonval et al., 2011). By contrast, PKMYT1
knockdown either fails to affect the timing of mitotic entry and
exit of HeLa cells or does so modestly, despite dramatically
reducing CDK1-T14 phosphorylation, without affecting CDK1-
Y15 (Nakajima et al., 2008; Coulonval et al., 2011; Villeneuve
et al., 2013). Thus, in mammals it is unclear whether PKMYT1
is required for regulating cyclin B/CDK1 activity during the cell
cycle, whereas there is ample evidence that WEE1 activity plays
key roles in preventing premature mitosis.
Given our results, we were interested to determine how
PKMYT1 and WEE1 might have roles in specifically sustaining
GSC viability. We began by examining the effects of PKMYT1
and WEE1 inhibition on CDK1/2 T14 and Y15 phosphorylation
in our NSC isolates, which permit KO of PKMYT1 without signif-
icant loss of viability (Figure 4A). In NSC-CB660s, we observed
that PKMYT1 KO results in dramatic reduction of PKMYT1 pro-
tein and CDK1-T14 phosphorylation with little or no effect on
CDK1/2 Y15, consistent with previous studies. However, we
find that PKMYT1 does in fact act redundantly with WEE1 to
phosphorylate CDK1-Y15 in NSCs. Western blot analysis shows
that PKMYT1 activity sustains CDK1-Y15, but not CDK2-Y15,
phosphorylation in the presence of a potent and specific WEE1
inhibitor (MK1775) (Figures 4A and 4B).
To investigate these effects phenotypically, we used time-
lapse microscopy to measure mitotic transit times (MTTs) (from
nuclear envelop break down to cytokinesis). In Drosophila, loss
of myt1 and wee1 dramatically increases the mitotic index of
imaginal wing disc cells (Jin et al., 2008), and a similar phenotype
is observed in HeLa cells overexpressing CDK1-T14A-Y15F,
which cannot be phosphorylated by PKMYT1 or WEE1 activity
(Krek and Nigg, 1991). We reasoned that this is likely due to acti-
vation of the spindle assembly checkpoint (SAC), which blocks
anaphase until end-on attachment of kinetochores and microtu-
bules has occurred, and chromosomes are properly aligned and
stable (Santaguida and Musacchio, 2009); thus, we would
expect MTT to be similarly delayed in our cells. First examining
NSCs, we find that KO of PKMYT1 or WEE1 inhibition alone
led to modest increases in MTT, where average MTT in control(E) In vitro viability assays retesting individual sgRNAs in multiple GSC isolates
12 days following selection or cultured for 18 days following selection and counted
sgControl. See Table S6 for Student’s t tests. TCGA subtypes: p, proneural; m,
plemental Experimental Procedures for details).
Cell Repcells is 37min compared to 47–51min (Figures 4C and 4D). How-
ever, loss of PKMYT1 andWEE1 activity together resulted in syn-
ergistic increases in MTTs to over 100 min on average with many
cells well over 150 min (Figures 4C and 4D). Importantly,
concomitant synergistic increases in cell death during mitosis
and cytokinesis failure were also observed (Figure 4E). Visual in-
spection of double inhibited cells with extended MTTs indicated
that they spend most of their time arrested at metaphase,
consistent with a SAC-induced arrest (data not shown).
We next repeated the same set of experiments in parallel in
NSC-CB660s and GSC-0827s, this time using a small interfering
RNA (siRNA) pool to inhibit PKMYT1, which allowed for better
control of timing of PKMYT1 inhibition in GSCs. Importantly,
the siRNA pool resulted in dramatic loss of PKMYT1 protein
expression (Figure 5D). In NSC-CB660s, the siPKMYT1 pool pre-
cisely phenocopied the effects of PKMYT1 KO, showing the
same increases in MTTs for PKMYT1 alone and together with
WEE1 inhibition (Figure 5A). By contrast and strikingly, in GSC-
0827s, inhibition of PKMYT1 or WEE1 alone was sufficient to
cause dramatic increases in MTTs similar to those observed
for double inhibition in NSCs (Figure 5B). As before, extended
MTTs were associated with cell death during mitosis and also
cytokinesis failure (Figure 5C). However, unlike NSCs, PKMYT1
depletion or WEE1 inhibition alone in GSCs resulted in cell death
during mitosis and also cytokinesis failure, and double treatment
resulted in themajority of the cells experiencing cell death during
mitosis. Consistent with this notion, dose-response curves of
WEE1 inhibitor alone also showed that GSCs are particularly
sensitive, but not NSC-CB660s (Figure 5F). Furthermore, knock-
down of PKMYT1 also compromised growth of GSC-0827s in
limiting dilution sphere formation assays, a surrogate assay for
self-renewal (Figure 5E). Importantly, these data demonstrate
that PKMYT1 and WEE1 are synthetic lethal in NSCs and act
redundantly to facilitate mitosis in human NSCs, and that this
redundancy is lost in GBM cells, giving rise to differential require-
ment for PKMYT1.
Oncogenic Activation of EGFR and AKT1 Sensitize NSCs
to Loss of PKMYT1 Function
We next wondered what could cause loss of PKMYT1 andWEE1
redundancy in GSCs. Previous studies have established that the
AKT and MAP kinase pathways can negatively impact PKMYT1
or WEE1 activity during meiosis/oocyte maturation (Okumura
et al., 2002; Palmer et al., 1998) and the somatic cell cycle (Ka-
tayama et al., 2005; Villeneuve et al., 2013). In human cells, AKT
has been shown to directly phosphorylate WEE1 at Ser-642,
causing its retention in the cytoplasm and loss of WEE1 activity
(Katayamaet al., 2005). In addition,MEK1activity has been impli-
cated in downregulation of PKMYT1 activity as HeLa cells enter
mitosis (Villeneuve et al., 2013). Since activation of PI3K and
RTK signaling cascades are prominent features of GBM tumors,
we next asked whether altering these pathways would be suffi-
cient to trigger PKMYT1 KO sensitivity in our NSCs.of different TCGA subtypes for genes indicated. Samples were outgrown for
with each split every 5–7 days to determine total cell number and normalized to
mesenchymalm; c, classical; or *, unable to classify (see Table S7 and Sup-
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Figure 4. Molecular and Phenotypic Characterization of PKMYT1 Function in GSCs and NSCs
(A) PKMYT1 and WEE1 act redundantly to phosphorylate Cdk1-Y15 in NSC-CB660s. Western blot analysis on whole-cell lysates (WCLs) or following immu-
noprecipitation (IP) of CDK1 or CDK2. NSC-CB660s were outgrown for 14 days following selection and then treated with 300 nM of MK1775 (WEE1 inhibitor) for
6 hr or mock treated. PKMYT1 antibody recognizes a non-specific protein that appears below PKMYT1 predicted molecular weight.
(B) Semi-quantification of western blot in (A) using ImageJ. Each band was normalized to their respective sgControl (-MK1775) sample.
(C) Representative images from time-lapse microscopy. NSC-CB660s were transduced with individual sgPKMTY1 and sgControl LV constructs, selected for
4 days, and outgrown for 15 days. Cells were then treated with 300 nM of the WEE1 inhibitor MK1775 or mock treated, followed by time-lapse microscopy for
72 hr. Images were acquired at 50-min intervals. Mitotic transit time was analyzed for individual cells following 6 hr of WEE1 inhibition.
(legend continued on next page)
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Figure 5. Loss of PKMYT1 and WEE1
Redundancy in GSC-0827 Cells
(A and B) Quantitation of mitotic transit times
(MTTs) of individual NSC-CB660s (A) and GSC-
0827s from (B) after PKMYT1 depletion, –/+ WEE1
inhibition (minimum of 6 hr). Cells were trans-
fected, treated with MK1775 (300 nM) or mock
treated (48 hr after initial transfection), and sub-
jected to time-lapse microscopy for 48 hr. Mann-
Whitney test; nR 60 cells/condition; ±SD.
(C) Outcome of each mitosis from cells counted in
(A) and (B).
(D) Protein expression levels of PKMYT1 depletion
by RNAi –/+ WEE1 inhibition in NSCs and GSCs.
PKMYT1 depletion with siRNAs in NSC-CB660
and GSC-0827 –/+ MK1775 (WEE1 inhibitor).
Western blot analysis on whole-cell extracts that
were transfected with siControl or siPKMYT1 (see
Supplemental Experimental Procedures) for 24 hr.
Following 48 hr from the initial transfection, cells
were treated with 300 nM of MK1775 (WEE1 in-
hibitor) for 6 hr or mock treated and harvested for
protein extraction.
(E) Limiting dilution sphere formation assays for
GSC-0827s that were treated to knockdown
PKMYT1. Cells were transfected with siControl or
siPKMYT1 for 24 hr. Cells were then harvested and
plated into 96-well plates at various seeding den-
sities (0.125–256 cells per well, ten wells per con-
dition). Linear regression analysis was performed
to generate each line per sample, and then each
line was compared (p value).
(F) WEE1 inhibitor dose-response curves for NSC-
CB660s and GSC-0827s. A differential response is
observed between NSC-CB660s and GSC-0827s
treated with the WEE1 inhibitor MK1775. Cells
were plated into 96-well plates and treated with
various doses of the WEE1 inhibitor dissolved in
0.18% DMSO 24 hr later. Following 72 hr post-
treatment, viability was assessed using CellTiter-
glo (Promega). Samples were normalized to the
DMSO only control sample, and the viability of
GSC-0827s was compared to NSC-CB660s at
each dose (Student’s t test [unpaired, unequal
variance]; five to six replicates per dose for each
line).To this end, we used constitutively active alleles of EGFR*
(EGFRvIII) (Bachoo et al., 2002) and AKT1* (myristoylation
tagged) (Boehm et al., 2007) in combination with TERT, domi-
nant-negative TP53DD, and CCND1+CDK4R24C (p16 resistant)
(Kendall et al., 2005) in NSC-CB660s. Note that manipulating
the p53 and Rb axis is required to bypass EGFR* induced senes-(D) Quantitation of mitotic transit times (MTTs) of individual NSC-CB660s from (C) after PKMYT1 KO, –/+ WE
outgrown for 15 days following selection, treated with MK1775 (300 nM) or mock treated, and subjected to tim
nR 60 cells/condition; ±SD.
(E) Quantification of phenotypic outcome of mitosis from (C) and (D). See Supplemental Experimental Proc
mitosis when nuclear envelope breakdown was visible.
Cell Reports 13, 2425–2439, Decence or apoptosis in our NSCs. Figures
6A and 6B shows the consequences of
various combinations of these humanoncogenes on CDK1-T14 and CDK1/2-Y15 phosphorylation
levels. Interestingly, adding EGFR* and then AKT1* to these cells
dramatically suppressed T14 and Y15 phosphorylation to
2-fold below the baseline found in NSCs and >3-fold from
levels found in TP53/RB-axis altered cells (which were higher
than baseline). AKT1* alone, however, had no effect. Instead,E1 inhibition (minimum of 6 hr). NSC-CB660s were
e-lapse microscopy for 72 hr. Mann-Whitney test;
edures for details. A cell was considered to enter
cember 22, 2015 ª2015 The Authors 2433
050
100
150
200
250
300
+WEE1 inhibitor 
0
200
400
600
800
1000
+WEE1 inhibitor 
M
ito
tic
 T
ra
ns
it 
Ti
m
e 
(m
in
s)
M
ito
tic
 T
ra
ns
it 
Ti
m
e 
(m
in
s)
Avg time= 40 49 51 102 Avg time= 69 129 84 272
p<0.0001p=0.0001 p<0.0001 p=0.0002 p<0.0001
n=65 n=65 n=65 n=66
n=65 n=65 n=66n=70
100.0%
100.0%
95.4%
3.1%1.5%
98.5%
1.5%
62.1%
25.8%
12.1%
70.0%
8.6% 21.4%
96.9%
3.1%
16.7%
56.1%
27.3%
siControl siControlsiPKMYT1 siPKMYT1
+WEE1 inhibitor
αP-Y15
αCDK1 P-T14
αCDK1
αHistone H4
NSC-CB660
- + - - + AKT1*
EGFR*
CCND1+CDK4R24C
TP53DD+TERT
- - - + +
- - + + +
- - + + +
0.0
0.5
1.0
1.5
2.0
CDK1 P-T14 P-Y15
R
el
at
iv
e 
to
 C
D
K
1 
ex
pr
es
si
on
 
siControl siPKMYT1 siControl siPKMYT1siControl siPKMYT1 siControl siPKMYT1
A B
C D
E
NSC-CB660
TP53DD+TERT+CCND1+CDK4R24C
NSC-CB660
TP53DD+TERT+CCND1+CDK4R24C
AKT1*+EGFR*
TP53DD+TERT+
CCND1+CDK4R24C+
AKT1*+EGFR*
TP53DD+TERT+
CCND1+CDK4R24C
Successful mitosis
Cytokinesis failure
Cell death during mitosis
1    2   3    4    5
1    2   3    4    5 1    2   3    4    5
Figure 6. Expression of Constitutively
Active Alleles of EGFR and AKT Sensitize
NSCs to PKMYT1 Depletion
(A and B) EGFR* and AKT* cause depletion of
steady-state levels of CDK1/2-Y15 and CDK1-T14
phosphorylation in NSC-CB660s. (A) Western blot
analysis of total CDK1/2-Y15-P and CDK1-T14-P
using whole-cell lysates (WCL). Histone H4 was
used as a loading control. Lane number corre-
sponds to its respective number in (B). Note that
p53 and RB-axis pathway perturbations are
required to bypass EGFR*-induced senescence
and apoptosis in NSCs. Thus, EGFR* experiments
could not be carried out alone. (B) Semi-
quantitative analysis of western blot from (A).
Samples were first normalized to their respective
loading control followed by their respective CDK1
expression.
(C and D) Mitotic transit time of individual geneti-
cally altered NSCs after PKMYT1 depletion, –/+
WEE1 inhibition (minimum of 6 hr). Cells were
transfected, treated with MK1775 (300 nM) or
mock treated (48 hr after initial transfection), and
subjected to time-lapse microscopy for 48 hr.
Mann-Whitney test; nR 65 cells/condition; ±SD.
(E) Outcome of each mitosis from cells counted in
(C) and (D).AKT1* potentiated the effect of EGFR*. These results demon-
strate that activation of the EGFR and AKT pathways is sufficient
to suppress the steady-state levels of CDK1-T14 and CDK1/2-
Y15 phosphorylation in NSCs.
To determine whether EGFR* and AKT1* affected
the requirement for PKMYT1, we again performed MTT assays.
We found that NSC-CB660s with TERT+TP53DD+
CCND1+CDK4R24C behaved exactly like unmanipulated NSCs
(Figure 6C). Importantly, however, the addition of EGFR* and
AKT1* to these cells in the presence of siPKMYT1 produces
similar effects on MTTs that were observed for GSCs (Fig-
ure 6D), where siPKMYT1 almost doubled MTTs. This pattern
also extends to increases in frequency of unsuccessful mitoses
(Figure 6E), with dramatic increases in cell death during mitosis
and cytokinesis failure. It is also interesting to note that EGFR*
and AKT* expression in control experiments increased NSC
MTTs from 40 to 69 min, as GSC-0827s show a similar trend.
Taken together, these results suggest that overactive EGFR
and PI3K signaling is sufficient to cause loss of redundancy
between PKMYT1 and WEE1 and differential sensitivity to2434 Cell Reports 13, 2425–2439, December 22, 2015 ª2015 The Authorsloss of PKMYT1, suggesting a general
mechanism for PKMYT1 requirement in
GSCs.
Examining CRISPR-Cas9-Triggered
Insertion-Deletion Mutation
Formation
Last, we confirmed sgRNA:Cas9 on-
target nuclease activity by deep
sequencing target sites for multiple
sgRNAs scoring in our screens. Whilewe observed high frequencies of on-target indel formation (Fig-
ures 7 and S7), consistent with other recent studies (Bae et al.,
2014; Shalem et al., 2014), we found unexpected biases in mu-
tation spectra. In many cases, single nucleotide insertions
were dramatically overrepresented (Figures 7B and 7C), biasing
indels toward reading frameshifts. In fact, only one of the seven
sgRNA-target site combinations tested showed nearly unbiased
reading frameshifts after indel formation, which would be ex-
pected to occur one-third of the time (Figure 7D). Without this
bias, small indels would have little affect on gene function nearly
a third of the time. Thereby, frameshift bias helps explain the
highly penetrant phenotypic effects produced by this technology
in human cells.
DISCUSSION
Here, we report the successful application of gene editing tech-
nology to identify and characterize genes promoting symmetric
in vitro expansion in human GSCs and NSCs. Our results
contribute to a growing body of work demonstrating the power
of CRISPR-Cas9 based approaches in human cells to identify
context-specific and generally lethal genes (Blomen et al.,
2015; Shi et al., 2015; Wang et al., 2015), in our case, using the
technology directly in patient-derived tumor isolates. Although
sgRNA-triggered KOs may not precisely replicate scenarios
with small molecule inhibitors, they do provide clues as to which
pathways and genes are likely to trigger a therapeutic response.
Our results speak to the notion of what counts as a good
mono-therapeutic target for GBM. From our screen results, we
expected to confirm the concept of ‘‘oncogene addiction’’ for
GBM, or that cancer cells become ‘‘addicted’’ to certain onco-
gene activities during their evolution, such that these activities
represent ‘‘rationale’’ therapeutic targets (Weinstein and Joe,
2008). However, we found very little overlap between GSC-spe-
cific screen hits and genes and pathways altered in GBM in gen-
eral or in the patient GSC isolates in which the screens were
performed. Perhapsmost importantly, we could not use descrip-
tive data sets from our patient samples to predict screen
outcome (and, thus, candidate therapeutic targets), which is
what current precision oncology paradigms attempt to do. While
this does not disprove the oncogene addiction hypothesis for
GBM, it does suggest that targeting sensitivities caused by
oncogenic activity, rather than the oncogenic activities them-
selves, may provide better therapeutic opportunities. This ap-
pears to be a recurring theme in our GBM work, as each of our
previous GSC-specific vulnerabilities found by shRNA screening
(Hubert et al., 2013; Ding et al., 2013; Toledo et al., 2014) are
likely caused by oncogene-induced changes in feedback regula-
tion of the underlying pathways.
Our screen results revealed at least two classes of GSC-
specific screen hits that arise from ‘‘individual-specific’’
dependencies found uniquely in patient samples and also
‘‘convergent’’ dependencies shared between the patient sam-
ples. Individual dependences likely arise from the specific epige-
netic and genetic alterations arising during patient tumor
evolution. While we were able to successfully retest several
screen hits specific to GSC-0131 and GSC-0827 (e.g.,
FBXO42, HDAC2, TFAP2C), we were unable to find evidence
that these hits correlated with a specific CNV, mutation, or tran-
scriptional signature from patient samples. More systematic
testing of these hits (e.g., larger sample size of GSCs and
comprehensive retesting of all hits) will be required to determine
whether they are truly unique to these isolates.
Convergent screen hits, which score in multiple GSCs regard-
less of particular oncogenic alterations, are more interesting
from a therapeutic perspective. We predict these to arise from
general oncogenic pathway activity rather than specific alter-
ations in pathways. Thereby, it is conceivable that convergent
screen hits may represent therapeutic targets that when in-
hibited are capable of producing durable responses in heteroge-
neous GBM tumors. Importantly, our follow-up experiments for
one such convergent hit, PKMYT1, suggests this would indeed
be the case. PKMYT1 arose from screens in patient isolates rep-
resenting different developmental subtypes (e.g., proneural
versus mesenchymal) and also distinct genetic alterations
(e.g., EGFR* versusNF1 loss and PTEN loss versus PI3KCA acti-
vation). Further, PKMYT1 dependency could be reproduced in
NSCs through ectopic activation of receptor tyrosine kinaseCell RepandPI3K pathways. This suggests thatPKMYT1 inhibition is syn-
thetic lethal with increased activity of these pathways, but not the
particular lesions per se found in the patient isolates. Arguably,
this makes PKMYT1 a very intriguing GBM candidate therapeu-
tic target.
From a biological standpoint, our results help re-discover
PKMYT1 function in human cells. PKMYT1 has largely been
overlooked as a key player in cell-cycle regulation in mammals,
despite convincing evidence in model metazoan systems that
it plays key roles in regulating cyclin B/CDK1 activity during
meiosis/oocyte maturation (Okumura et al., 2002; Palmer et al.,
1998) and entry into mitosis (Jin et al., 2008; Mueller et al.,
1995). We find that, in human NSCs, PKMYT1 acts redundantly
with WEE1 to both maintain CDK1-Y-15 phosphorylation and
to promote timely completion of mitosis. Previous work in
HeLa cells has demonstrated sole reliance on WEE1 for CDK1-
Y-15-P and preventing premature entry into mitosis and mitotic
catastrophe (Coulonval et al., 2011; Nakajima et al., 2008). Our
data, however, demonstrate that PKMYT1 activity can compen-
sate for both Y-15-P and preventing extended MTTs in WEE1
inhibited non-transformed NSCs (Figure 4). This is consistent
with the observation thatDrosophilawee1 andmyt1 have redun-
dant and overlapping roles during fly development (Jin et al.,
2008). We predict that the same redundancy will be observed
in other non-transformed vertebrate cell types.
We attribute the observed GSC-specific lethality of PKMYT1
KO to loss of redundancy of PKMYT1 and WEE1. In GSCs,
PKMYT1 loss alone leads to dramatic increases in MTTs, as
well as cell death during mitosis and cytokinesis failures
(Figure 5).
We show that activation of EGFR and AKT1 pathways sup-
press CDK1/2-Y15 and CDK1-T14 phosphorylation in NSCs
(Figure 6). This strongly suggests that activation of these path-
ways together results in net loss of inhibition of CDK1/2 during
the G2/M transition. It is conceivable that these effects are
mediated by direct negative regulation of PKMYT1 or WEE1
activity. However, other mechanisms are possible. This in-
cludes directly or indirect regulation of the activity of CDC25
phosphatase, which is responsible for removing CDK-T14
and Y15 phosphorylation and which has been shown to be a
target of EGFR signaling in a Drosophila model of glioma
(Read et al., 2009). Future experiments will be required to
address whether EGFR and AKT signaling acts through direct
or indirect regulation of PKMYT1 and/or WEE1 activity in
GBM cells.
While PKMYT1 function has not previously been studied in
GBM or other cancers, there has been great interest in WEE1
as a potential therapeutic target as a cytotoxic chemotherapy
and radiation sensitizer, since it is required for radiation-induced
arrest and repair (DeWitt Hamer et al., 2011; Mir et al., 2010). For
GBM, GSCs appear more resistant to radiation through
increased repair proficiency (Bao et al., 2006; Liu et al., 2006).
Thus, WEE1 inhibition may enhance radiation treatment. Though
the WEE1 inhibitor, MK1775, and temozolomide preclinical
combinational studies in mouse flank GBM models were highly
effective, the combinational treatment in mouse brain orthotopic
xenograft models were ineffective due to the limited heteroge-
neous distribution of MK1775 across the blood-brain barrierorts 13, 2425–2439, December 22, 2015 ª2015 The Authors 2435
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(Pokorny et al., 2015). Because the currentWEE1 inhibitor in clin-
ical trials is not effective in penetrating the blood-brain barrier,
future studies are warranted in order to identify PKMYT1-spe-
cific inhibitors, as our results suggest that inhibiting PKMYT1’s
kinase activity alone may be a GBM-therapeutic target. Howev-
er, it is currently unclear whether PKMYT1 inhibition would syn-
ergizewith cytotoxic therapies that engageWEE1 or whether this
could suppress requirement for PKMYT1. Future studies will
have to address this and also create pipelines for the identifica-
tion of PKMYT1-specific inhibitors, which, to our knowledge,
have not been successfully developed (Rohe et al., 2014a,
2014b).
EXPERIMENTAL PROCEDURES
All in vivo experiments were conducted in accordance with the NIH Guide for
the Care and Use of Experimental Animals, and with approval from the Fred
Hutchinson Cancer Research Center Institutional Animal Care and Use Com-
mittee (IR#1457).
Cell Culture
GSC and NSC lines were grown in N2B27 neural basal media (STEMCELL
Technologies) supplemented with EGF and FGF-2 (20 ng/ml) (PeproTech) on
laminin (Sigma) -coated polystyrene plates and passaged as previously
described (Pollard et al., 2009).
CRISPR-Cas9 Screening
A human genome-wide CRISPR-Cas9 library (Shalem et al., 2014) was used in
lentiviral pooled format to transduce GSCs and NSCs. For each screen repli-
cate, cells were transduced at 500-fold representation of the library (at
30% infection efficiency). 2 days after transduction, puromycin was added
(1–4 mg/ml) for 3 days. A portion of cells were harvested as day 0 time point.
The rest of the cells were then passaged to maintain 500-fold representation
and cultured for an additional 21–23 days (eight to ten cell doublings). Genomic
DNA was extracted, and a two-step PCR procedure was employed to amplify
sgRNA sequences and then to incorporate deep sequencing primer sites onto
sgRNA amplicons. Purified PCR products were sequenced using HiSeq 2500
(Illumina). Raw and mapped data files are available at the Gene Expression
Omnibus databasae (GEO: GSE70038).
Additional experimental procedures are available in Supplemental
Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and seven tables and can be found with this article online at
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